IL298978A - Tandem anellovirus constructs - Google Patents

Tandem anellovirus constructs

Info

Publication number
IL298978A
IL298978A IL298978A IL29897822A IL298978A IL 298978 A IL298978 A IL 298978A IL 298978 A IL298978 A IL 298978A IL 29897822 A IL29897822 A IL 29897822A IL 298978 A IL298978 A IL 298978A
Authority
IL
Israel
Prior art keywords
anellovirus
sequence
nucleic acid
genetic element
cell
Prior art date
Application number
IL298978A
Other languages
English (en)
Hebrew (he)
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of IL298978A publication Critical patent/IL298978A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
IL298978A 2020-06-12 2021-06-11 Tandem anellovirus constructs IL298978A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038483P 2020-06-12 2020-06-12
US202163146963P 2021-02-08 2021-02-08
PCT/US2021/037091 WO2021252955A1 (en) 2020-06-12 2021-06-11 Tandem anellovirus constructs

Publications (1)

Publication Number Publication Date
IL298978A true IL298978A (en) 2023-02-01

Family

ID=78845951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298978A IL298978A (en) 2020-06-12 2021-06-11 Tandem anellovirus constructs

Country Status (12)

Country Link
US (1) US20230348933A1 (cg-RX-API-DMAC10.html)
EP (1) EP4165198A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023530278A (cg-RX-API-DMAC10.html)
KR (1) KR20230036110A (cg-RX-API-DMAC10.html)
CN (1) CN116075591A (cg-RX-API-DMAC10.html)
AU (1) AU2021288320A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025190A2 (cg-RX-API-DMAC10.html)
CA (1) CA3186894A1 (cg-RX-API-DMAC10.html)
IL (1) IL298978A (cg-RX-API-DMAC10.html)
MX (1) MX2022015802A (cg-RX-API-DMAC10.html)
TW (1) TW202223095A (cg-RX-API-DMAC10.html)
WO (1) WO2021252955A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function
CN119331914A (zh) * 2024-10-17 2025-01-21 中科开浦生物科技(湖北)有限公司 一种指环病毒感染性克隆的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
RU2553223C2 (ru) * 2009-08-21 2015-06-10 Виргиния Тек Интеллекчуал Пропертиз, Инк. ВАКЦИНЫ НА ОСНОВЕ СВИНОГО ВИРУСА Torque teNO И СПОСОБЫ ДИАГНОСТИКИ ИНФЕКЦИЙ, ВЫЗВАННЫХ ЭТИМ ВИРУСОМ
ES2777217T3 (es) * 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
RU2744193C2 (ru) * 2015-10-16 2021-03-03 Канзас Стейт Юниверсити Рисерч Фаундейшн Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
CA3066750A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
CA3121528A1 (en) * 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
EP3894567A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering intracellular therapeutic modalities

Also Published As

Publication number Publication date
WO2021252955A1 (en) 2021-12-16
MX2022015802A (es) 2023-03-28
US20230348933A1 (en) 2023-11-02
CN116075591A (zh) 2023-05-05
KR20230036110A (ko) 2023-03-14
EP4165198A4 (en) 2024-10-23
TW202223095A (zh) 2022-06-16
AU2021288320A1 (en) 2023-01-19
EP4165198A1 (en) 2023-04-19
BR112022025190A2 (pt) 2023-03-07
CA3186894A1 (en) 2021-12-16
JP2023530278A (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
US11446344B1 (en) Anellovirus compositions and methods of use
US20260009050A1 (en) Anellosomes for delivering secreted therapeutic modalities
US20230279423A1 (en) Compositions comprising curons and uses thereof
US20220073950A1 (en) Anellosomes for delivering protein replacement therapeutic modalities
US20230340527A1 (en) Baculovirus expression systems
US20220042042A1 (en) Anellosomes and methods of use
AU2019396516B2 (en) Anellosomes for delivering intracellular therapeutic modalities
US20230348933A1 (en) Tandem anellovirus constructs
US20240254512A1 (en) Anellovectors and methods of use
US20230227849A1 (en) Methods of identifying and characterizing anelloviruses and uses thereof
US20240123083A1 (en) Hybrid aav-anellovectors
CA3199750A1 (en) Chicken anemia virus (cav)-based vectors